Investment Banking

The Quarterly Rx: Q1 2023 U.S. Biopharma Recap

The year kicked off with renewed optimism for the biopharma sector, but “macro” concerns resurfaced to end the quarter. Demand for catalyst-driven offerings remained strong in the public markets, but the private market continued to slow. There is a strong desire to see more SMID-cap M&A to recycle capital into the sector, while reverse mergers continue to provide companies with an alternative path to the public markets. The quarter did see the long-awaited “big M&A” of Seagen by Pfizer, the largest biopharma deal since 2019.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q1 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit